Gemcitabine News and Research

RSS

Gemcitabine is the active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used together with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite

In vitro testing suggests effective novel drug combinations for SARS-CoV-2

A recent study published on the preprint server bioRxiv* in September 2020 shows the value of drug combinations to enhance the therapeutic and preventive efficacy of such repositioned drugs in standard antiviral therapy.

20 Sep 2020

Sortilin may hold the key to developing more effective treatment for pancreatic cancer

Pancreatic cancer has an extremely poor prognosis; it is the third most common cause of cancer deaths in the United States.

20 Aug 2020

Cocktail of chemotherapy drugs may be safe, effective for patients with metastatic pancreatic cancer

Pancreatic cancer carries a poor prognosis, and it often goes undetected until advanced stages. A new BJS (British Journal of Surgery) study indicates that a certain cocktail of chemotherapy drugs may be a safe and effective treatment option for patients with a metastatic form of the disease.

8 Jul 2020

New treatment may improve the quality of life for patients with mesothelioma

A novel treatment for advanced mesothelioma is safe and effective and may improve the quality of life for patients who have few treatment options, according to a research abstract presented during a virtual session of the Society of Interventional Radiology's 2020 Annual Scientific Meeting on June 14.

15 Jun 2020

Study compares cediranib plus olaparib and standard of care therapy for platinum-sensitive ovarian cancer

Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival (PFS) outcomes for women with platinum-sensitive ovarian cancer; however, activity between the treatments was similar in patients.

30 May 2020

SWOG scientists to deliver online presentations at ASCO20 Virtual Scientific Program

Researchers from SWOG, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, will make 31 presentations as part of the ASCO20 Virtual Scientific Program, the online annual meeting of the American Society of Clinical Oncology (ASCO), which runs May 29-31.

19 May 2020

Talazoparib did not show overall survival benefit in patients with advanced BRCA-mutated breast cancer

New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.

27 Apr 2020

Despite failures, chemotherapy still promising against fatal pediatric brain cancer

The pediatric brain cancer known as diffuse intrinsic pontine glioma is almost uniformly fatal. In part, this is due to where and how it grows, forming as a diffuse net of cells in a part of the brainstem called the pons, which controls essential functions like breathing and swallowing.

25 Mar 2020

Overview of prognostic and predictive factors in pancreatic cancer

Oncotarget Volume 11, Issue 10 reported that there are not standardized predictive biomarkers able to identify patients who benefit most from treatments.

13 Mar 2020

The Pancreatic Cancer Collective awards additional funding of $16 million for new therapies

The Pancreatic Cancer Collective, the strategic partnership of Lustgarten Foundation and Stand Up To Cancer, has awarded additional funding of up to $16 million to four teams of top researchers as part of its "New Therapies Challenge Grants," the American Association for Cancer Research, Scientific Partner of SU2C, announced today.

5 Mar 2020

Inexpensive drug may be used to counteract treatment resistance in patients with leukemia

A common and inexpensive drug may be used to counteract treatment resistance in patients with acute myeloid leukemia, one of the most common forms of blood cancer.

17 Jan 2020

Atlantic Health System Cancer Care enrolling patients in five pancreatic cancer studies

November is National Pancreatic Cancer Awareness month. This year alone, more than 56,000 Americans will be diagnosed with pancreatic cancer. Pancreatic tumors are particularly aggressive and hard to treat "due to a mutational profile that makes it resistant to therapies that work better for other tumor types," explains Angela Alistar, MD, medical director of GI Oncology at Morristown Medical Center.

30 Oct 2019

Gemcitabine News and Research

In vitro testing suggests effective novel drug combinations for SARS-CoV-2

Sortilin may hold the key to developing more effective treatment for pancreatic cancer

Cocktail of chemotherapy drugs may be safe, effective for patients with metastatic pancreatic cancer

New treatment may improve the quality of life for patients with mesothelioma

Study compares cediranib plus olaparib and standard of care therapy for platinum-sensitive ovarian cancer

SWOG scientists to deliver online presentations at ASCO20 Virtual Scientific Program

Talazoparib did not show overall survival benefit in patients with advanced BRCA-mutated breast cancer

Despite failures, chemotherapy still promising against fatal pediatric brain cancer

Overview of prognostic and predictive factors in pancreatic cancer

The Pancreatic Cancer Collective awards additional funding of $16 million for new therapies

Inexpensive drug may be used to counteract treatment resistance in patients with leukemia

Atlantic Health System Cancer Care enrolling patients in five pancreatic cancer studies

Certain fungi increase pancreatic cancer risk, study finds

Scientists identify pathway for treatment-resistant lung cancer

Study opens a promising new front in the fight against pancreatic cancer

New drug may enhance efficacy of chemotherapy in pancreatic cancer

The gift of longevity for a pancreatic cancer patient

Study shows synergistic effects of drugs that inhibit cell division in pancreatic cancer

Targeted pancreatic cancer drug shows promise in clinical trials

New drug to treat pancreatic cancer shows promising results in clinical trial

ACROBiosystems and the Fight Against COVID-19

Monoclonal Antibody Development and Characterization

Eliminating the Cold Chain with COVID-19 Molecular Transport Media

Latest News